Pathways to Precision: Integrating Genetic Counseling and Testing Into Cancer Care

Elevate your expertise in personalized cancer care with our free, enduring online webinar! Join Dr. Filipa Lynce, Director of the Inflammatory Breast Center at Dana-Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School, alongside Catherine Skefos, MA, MS, CGC, Certified Genetic Counselor in the Clinical Cancer Genetics Program at the University of Texas MD Anderson Cancer Center. Gain practical strategies to overcome barriers to genetic testing, explore groundbreaking clinical trial data, and master counseling techniques to guide patients and families through complex genetic information. Don't miss this dynamic, on-demand opportunity to enhance your skills and transform patient outcomes. Start the activity now!

STATEMENT OF NEED

Precision medicine is a cutting-edge approach that incorporates an individual’s genomic, environmental, and lifestyle information to deliver personalized healthcare. Genetic testing and counseling are crucial components of precision medicine, enabling clinicians to deliver the right care to the right patient at the right time (Turbitt et al, 2023). However, genetic testing often remains an untapped resource for patients who may benefit from genetic risk assessment and cancer surveillance, and barriers at the patient, provider, and systems level may impede its integration into the clinic (Dusic et al, 2022). In this activity, Dr. Filipa Lynce, Director of the Inflammatory Breast Center at Dana-Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School, and Catherine Skefos, Certified Genetic Counselor in the Clinical Cancer Genetics Program at the University of Texas MD Anderson Cancer Center, will explore solutions for overcoming barriers to genetic testing referral, clinical trial data and real-world evidence for targeted therapies for BRCA-mutated solid tumors, and strategies for effectively counseling patients regarding complex genetic information.

TARGET AUDIENCE

Primary care providers (PCPs), medical oncologists, medical geneticists, genetic counselors, oncology nurses, and advanced practice providers involved in referring or conducting genetic counseling and testing of patients with or at risk of cancer.

Upon completion of this activity, participants should be able to

• Explain the rationale behind referring patients for genetic risk assessment and testing and selecting the appropriate testing methodology
• Identify potential solutions to common barriers to genetic testing referral and integration into clinical practice
• Evaluate existing and novel targeted therapies for BRCA-mutated solid tumors based on key clinical trial data and real-world evidence
• Apply expert strategies to clearly communicate complex genetic information, counseling process, and referral pathways to patients and family members

PROVIDED BY

JOINTLY ACCREDITED PROVIDER

In support of improving patient care, i3 Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIANS

i3 Health designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

By providing this information, participants are agreeing to allow i3 Health to share this information with the ACCME.

Physician Assistants/Associates

i3 Health has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until 12/2/25. PAs should only claim credit commensurate with the extent of their participation.

Nurse Practitioners

The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.

Nursing Continuing Professional Development

A maximum of 1.0 ANCC contact hour may be earned by learners who successfully complete this nursing continuing professional development activity. This activity has been designated for 0.6 ANCC contact hours of pharmacology credit for Advanced Practice Registered Nurses.

Provider approved by the California Board of Registered Nursing, Provider Number 15824, for 1.0 ANCC contact hour. 

ONCC RECERTIFICATION

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points.

ONCC review is only for designating content to be used for recertification points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of NCPD to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification may be used in relation to the program.

OCN®, CPHON®, CBCN®, AOCNP®, AOCNS®, and BMTCN® renewal candidates may apply 1.0 ILNA point toward:

• Care Continuum (OCN®, CBCN®, CPHON®, AOCNP®)
• Diagnosis and Staging (CBCN®)
• Nursing Practice (CBCN®)
• Oncology Nursing Practice (OCN®)
• Professional Practice/Performance (BMTCN®, AOCNP®)
• Psychosocial Dimensions of Care (AOCNP®, CPHON®, OCN®, CBCN®)
• Roles of the APRN (AOCNP®)

Please note that some of the course content applies to multiple content areas. The numerical value above indicates the maximum amount of points that can be claimed in each domain. The total amount of ILNA points claimed may not exceed the total amount of NCPD awarded from this course.

Genetic Counselors

This activity is eligible for Category 2 NSGC credit for genetic counselors. Genetic counselors are encouraged to submit their Category 2 credit on the NSGC website at nsgc.org.

DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH INELIGIBLE COMPANIES

i3 Health endorses the standards of the ACCME and ANCC that require everyone in a position to control the content of a CME/NCPD/CE activity to disclose all financial relationships with ineligible companies that are related to the content of the CME/NCPD/CE activity. CME/NCPD/CE activities must be balanced, independent of commercial bias, and promote improvements or quality in health care. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.

A conflict of interest is created when an individual has an opportunity to affect CME/NCPD/CE content about products or services of an ineligible company with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.

i3 Health will identify, review, and mitigate all relevant financial relationships that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services.

Relevant financial relationships exist between the following individuals and ineligible companies:

The i3 Health planners, reviewers, and managers have nothing to disclose.

Filipa Lynce, MD, discloses that she has served on an advisory board or panel for AstraZeneca, Daiichi Sankyo, Eli Lilly, and Pfizer; and that she has received grants/research support from AstraZeneca, Gilead, Ideaya, Merck, Syndax, and Zentalis.

Catherine Skefos, MA, MS, CGC, has no relevant financial relationships to disclose.

i3 Health has mitigated all relevant financial relationships.

INSTRUCTIONS TO RECEIVE CREDIT

In order to receive credit for this activity, participants must view the video and submit a completed evaluation at the end of the activity.

TECHNOLOGY REQUIREMENTS FOR VIRTUAL CME | NCPD | CE ACTIVITIES

For virtual (asynchronous, archived live, home study; synchronous webinars) CME/NCPD/CE activities, include access to system requirements:

• The Internet browser(s) supported and minimum versions of each required by the learner to complete the online activity.
• The minimum memory, storage, processor, and Internet speeds require by the learner to complete the online activity.

UNAPPROVED USE DISCLOSURE

i3 Health requires CME/NCPD/CE faculty (speakers) to disclose to attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved), as well as any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling.

This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

DISCLAIMER

The information provided at this CME/NCPD/CE activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a health care provider relative to diagnostic and treatment options of a specific patient’s medical condition.

COMMERCIAL SUPPORT

This activity is supported by an independent educational grant from Merck Sharp & Dohme LLC.